Sarclisa is a novel monoclonal antibody directed against the CD38 receptor on the surface of myeloma cells. This is described as a targeted anti-myeloma therapy. Sarclisa both kills myeloma cells directly and recruits surrounding immune cells to enhance the killing process.

*updated 12/3/2024